The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. Many investors ...
CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...
Viking thinks the oral alternative offers a smooth transition from the subcutaneous form and might appeal to individuals reluctant about injectable therapies. The business completed an End-of-Phase 2 ...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...
Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...
Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...
In early 2024, Viking announced positive top-line results from its Phase 2 VENTURE study of VK2735 in obesity. The VENTURE trial successfully achieved its primary and all secondary endpoints ...
The injectable version of the candidate, tentatively named VK2735, reduced obesity patients' weight by 14.7% after 13 weeks in a relatively small phase 2 trial. Viking continued to impress ...